| Literature DB >> 35586304 |
Hongliang Zhang1, Zhenyan Zhao1, Jing Yao1, Jie Zhao1, Tao Hou2, Moyang Wang1, Yanlu Xu1, Bincheng Wang1, Guannan Niu1, Yonggang Sui1, Guangyuan Song3, Yongjian Wu4.
Abstract
Background: The association between prior percutaneous coronary intervention (PCI) and prognosis after coronary artery bypass grafting (CABG) remains uncertain. We aimed to evaluate the aforementioned association in a meta-analysis.Entities:
Keywords: all-cause mortality; coronary artery bypass grafting; major adverse cardiovascular events; meta-analysis; percutaneous coronary intervention
Year: 2022 PMID: 35586304 PMCID: PMC9109498 DOI: 10.1177/20406223221078755
Source DB: PubMed Journal: Ther Adv Chronic Dis ISSN: 2040-6223 Impact factor: 4.970
Figure 1.Flowchart of database searches and study identification.
Characteristics of the included studies investigated the association between prior PCI and clinical outcomes of CABG.
| Study | Country | Design | No. of patients, | Mean age (years) | Male (%) | DM (%) | Patients with prior PCI,
| PCI type | Follow-up duration | Variables adjusted |
|---|---|---|---|---|---|---|---|---|---|---|
| Barakate | Australia | Retrospective | 12,270 | 61.3 | 79 | 15.2 | 361 | PTCA | 1 month | None |
| Hassan | Canada | Retrospective | 6032 | NR | 76.1 | 30.3 | 919 | NR | In-hospital | Age, sex, comorbid disease burden, level of acuity, and surgical center using multivariate techniques |
| van den Brule | The Netherlands | Retrospective | 1254 | 64.1 | 73.8 | 6.3 | 113 | PTCA or stent | 1 year | Age, sex, pulmonary disease, preoperative MI, diseased vessels, NYHA class, LV function, reintervention, postoperative arrhythmia, perioperative MI, renal complications, and stroke |
| Gurbuz | Turkey | Retrospective | 611 | 67.4 | 55 | 18.4 | 190 | PTCA, stent, cutting-balloon, atherectomy, and brachytherapy | 2.4 years | Age, sex, COPD, smoking, and LVEF |
| Thielmann | Germany | Retrospective | 3275 | 66.9 | 75.2 | 29.6 | 649 | BMS (85.4%), DES (14.6%) | In-hospital | Age, sex, obesity, LM lesions, LVEF, PAD, COPD, DM, HTN, dyslipidemia, angina class, previous MI, and renal disease |
| Pliam | The United States | Retrospective | 1471 | 68.8 | 64.5 | 40.7 | 154 | BMS (92.9%), DES (7.1%) | 4.1 years | None |
| Gaszewska | Poland | Retrospective | 311 | 63.1 | 79.8 | 17 | 162 | BMS | 3 years | None |
| Kinoshita | Japan | Retrospective | 275 | 67.5 | 69.7 | 100 | 79 | PTCA (28%), BMS (44%), DES (28%) | In-hospital | Age, sex, renal dysfunction, PAD, LVEF, history of MI, emergency of operation, IABP, NYHA class, COPD, and EuroSCORE |
| Yap | Australia | Retrospective | 13,184 | 65.9 | 78.1 | 32.3 | 1457 | PTCA or BMS | 3.3 years | Age, sex, HTN, DM, PAD, renal disease, cerebrovascular disease, respiratory disease, MI, CHF, NYHA class, LM lesions, and surgery type |
| Tran | The United States | Retrospective | 1758 | 62.9 | 74.2 | 100 | 221 | BMS or DES | 2 years | Age, sex, BMI, HTN, smoking, CHF, LVEF, NYHA class, family history of CAD, preoperative platelet use, arrhythmia, cerebrovascular accident, PAD, COPD, history of renal failure, and cross-clamp time |
| Bonaros | Austria | Retrospective | 758 | 66.4 | 74.7 | 22.7 | 306 | PTCA (2.6%), BMS (58.8%), DES (38.6%) | In-hospital | Age, sex, and EuroSCORE |
| Massoudy | Germany | Retrospective | 29,928 | 66.4 | 73.0 | 27.6 | 4176 | PTCA or stent | In-hospital | Age, sex, obesity, LM lesion, LVEF, PAD, COPD, DM, HTN, ever smoking, hyperlipidemia, previous MI, emergency, number of grafts, and year of surgery |
| Carnero Alcazar | Spain | Retrospective | 796 | 67.0 | 79.6 | 43.9 | 116 | BMS or DES | In-hospital | Age, sex, LVEF <40%, history of cerebrovascular disease, MI, number of diseased coronary vessels, and incomplete revascularization |
| Fukui | Japan | Retrospective | 545 | 68.8 | 79.8 | 47.3 | 154 | PTCA, BMS, or DES | In-hospital | None |
| Stevens | Canada | Retrospective | 9642 | 66.5 | 74.7 | 37.6 | 823 | PTCA or stent | 4.1 years | Age, sex, PAD, renal failure, arrhythmia, LVEF, cardiogenic shock, and LM lesions |
| Boening | Germany | Retrospective | 1092 | 70.0 | 71.9 | 100 | 185 | BMS (71.5%), DES (16.5%), or both (12%) | In-hospital | Age, sex, EuroSCORE, IABP, complete revascularization, and ECC time |
| Lisboa | Brazil | Prospective | 1099 | 63.6 | 73.7 | 46.5 | 161 | BMS (91.3%) and DES (8.7%) | In-hospital | Age, sex, LVEF, LM lesions, CHF, use IABP, COPD, CVD risk factors, and surgery type |
| Mannacio | Italy | Retrospective | 7855 | NR | 78.1 | 37.2 | 1021 | BMS (42%) and DES (858%) | 5 years | Age, sex, BMI, HTN, DM, PAD, respiratory disease, renal disease, MI, LVEF <40%, NYHA class, EuroSCORE, and LM lesions |
| Mehta | The United States | Retrospective | 34,316 | 61.0 | 73.6 | 37.9 | 4346 | NR | In-hospital | Age, sex, operative year, number of arterial and venous bypass grafts, CPB time, and performance of prior PCI |
| O’Neal | The United States | Retrospective | 13,354 | NR | 70.8 | 35.2 | 2532 | PTCA, BMS, or DES | 8.1 years | Age, sex, race, HTN, CAD, severity, CHF, and prior stroke |
| Velicki | Serbia | Retrospective | 950 | 62.4 | 77.2 | 28.8 | 131 | BMS (84%), DES (8.4%), or both (7.6%) | 1 month | None |
| Sánchez | Spain | Retrospective | 63,420 | 64.7 | 19.4 | 30.7 | 2942 | BMS or DES | In-hospital | Age, sex, year of surgery, emergency surgery, DM, dyslipidemia, HTN, smoking, previous MI, AF, COPD, CRF, CHF, PAD, cerebrovascular disease, MI at admission, and cardiogenic shock at admission |
| Fukui | Japan | Retrospective | 1166 | 68.2 | 79.9 | 46.7 | 269 | BMS (64.7%), DES (26.4%), or both (8.9%) | 3.6 years | None |
| Nauffal | The United States | Retrospective | 1583 | 64.6 | 63.2 | 100 | 202 | BMS or DES | 5 years | Age, sex, BMI, CHF, NYHA class, HTN, smoking, family history of CAD, chronic lung disease, cerebrovascular disease, PAD, perioperative medications, and characteristics of surgery |
| Luthra | The United Kingdom | Retrospective | 5058 | 65.3 | 83.1 | 25.6 | 424 | BMS or DES | 10 years | Age, sex, BMI, EuroSCORE, NYHA class and CCS angina grade, LVEF, nonsinus rhythm, pulmonary and neurologic medical history, DM, surgical urgency, LM lesions, number of vessels diseased, and history of HTN |
| Kamal | Egypt | Retrospective | 160 | 58.3 | 77.5 | 14.4 | 38 | NR | In-hospital | Age, sex, family history of CAD, smoking, DM, obesity, chronic lung disease, LVEF, NYHA class, LM lesions, and multivessel disease |
| Ueki | Japan | Retrospective | 48,051 | 68.3 | 78.2 | 43.4 | 12,457 | NR | In-hospital | Age, sex, BMI, HTN, smoking, CHF, LVEF, NYHA class, family history of CAD, preoperative platelet use, arrhythmia, cerebrovascular accident, PAD, COPD, history of renal failure, and perioperative medications |
| Cheng | China | Retrospective | 439 | 63.7 | 80.0 | 53.3 | 97 | PCI with stents | In-hospital | None |
| Biancari | International | Retrospective | 6563 | 67.5 | 83.4 | 30.5 | 1181 | DES (56.8%) and other stents | 1 year | Age, sex, year of surgery, emergency surgery, DM, dyslipidemia, HTN, smoking, previous MI, AF, COPD, CRF, CHF, PAD, cerebrovascular disease, MI at admission, perioperative medications, and operative data |
| Bugajski | Poland | Prospective | 211 | 61.2 | 74.4 | 25.1 | 99 | PCI with stents | 1 year | None |
| Nicolau | International | Retrospective | 1212 | 60.0 | 87.8 | 39.4 | 156 | NR | 9.8 years | Age, sex, region, eGFR, prior CABG, number and location of diseased vessels, HR, NYHA class, AF, moderate or severe mitral regurgitation, end-systolic volume index, DM, stroke, current smoking, chronic renal insufficiency, depression, and ACEI/ARB use |
| Hadadzadeh | Iran | Retrospective | 220 | 59.4 | 66.8 | 43.2 | 110 | PCI with stents | In-hospital | None |
| Miguel | Brazil | Retrospective | 3007 | 62.1 | 70.0 | 36.6 | 261 | NR | 5 years | Age, sex, DM, dyslipidemia, CHF, previous MI, and UA |
| Cheng | China | RC | 32,335 | 65.5 | 76.7 | 42.3 | 3025 | PCI with stents | 13 years | Age, sex, HTN, DM, dyslipidemia, other comorbidities, CCI, hospital type, on-pump or off-pump CABG, valves affected, and characteristics of previous PCI |
| Hakamada | Japan | RC | 1651 | 69 | 76.1 | 52.1 | 497 | PCI with stents | 8 years | Age, sex, BMI, HTN, dyslipidemia, DM, CKD, hemodialysis, prior stroke, prior MI, CHF, UA, preoperative IABP, urgency of procedure, smoking status, chronic lung disease, PAD, AF, LV systolic dysfunction, left main disease, other coronary lesion characteristics, CCS class, and NYHA class |
| Thielmann | Germany | PC | 2432 | 67.8 | 77.6 | 32.1 | 878 | NR | In-hospital | Age, sex, hyperlipidemia, PAD, LM lesion, prior MI, LVEF, Killip class, thrombolysis, and EuroSCORE |
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; BMS, bare metal stent; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCI, Charlson Comorbidity Index; CCS, Canadian Cardiology Society; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CRF, chronic renal failure; CVD, cardiovascular disease; DES, drug-eluting stent; DM, diabetes mellitus; ECC, extracorporeal circulation; eGFR, estimated glomerular infiltrating rate; EUROscore, European System for Cardiac Operative Risk Evaluation; HR, heart rate; HTN, hypertension; IABP, intra-aortic balloon pump; LM, left main; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NR, not reported; NYHA, New York Heart Association; PAD, peripheral artery disease; PC, prospective cohort; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; RC, retrospective cohort; UA, unstable angina.
Details of study quality evaluation via the Newcastle–Ottawa scale.
| Study | Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Outcome not present at baseline | Control for age and sex | Control for other confounding factors | Assessment of outcome | Enough long follow-up duration | Adequacy of follow-up of cohorts | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Barakate | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 6 |
| Hassan | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 |
| van den Brule | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Gurbuz | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Thielmann | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Pliam | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Gaszewska | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Kinoshita | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 |
| Yap | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Tran | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Bonaros | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Massoudy | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Carnero Alcazar | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| Fukui | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 5 |
| Stevens | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Boening | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 |
| Lisboa | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Mannacio | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Mehta | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| O’Neal | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Velicki | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 6 |
| Sánchez | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Fukui | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Nauffal | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Luthra | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Kamal | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Ueki | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Cheng | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 6 |
| Biancari | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Bugajski | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 7 |
| Nicolau | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 |
| Hadadzadeh | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 6 |
| Miguel | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Cheng | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Hakamada | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Thielmann | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
Figure 2.Forest plots for the meta-analysis of the associations between prior PCI and early outcomes after CABG: (a) early all-cause mortality and (b) early MACEs.
CABG, coronary artery bypass grafting; CI, confidence interval; MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
Figure 3.Forest plots for the meta-analysis of the associations between prior PCI and late outcomes after CABG: (a) late all-cause mortality and (b) late MACEs.
CABG, coronary artery bypass grafting; CI, confidence interval; MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
Results of univariate meta-regression analysis.
| Covariate | Coefficient | 95% CI | |
|---|---|---|---|
| Short-term mortality | |||
| No. of patients | −0.007 | −0.0162 to 0.0032 | 0.19 |
| Mean age (years) | −0.051 | −0.131 to 0.029 | 0.20 |
| Male (%) | 0.006 | −0.007 to 0.019 | 0.36 |
| DM (%) | 0.001 | −0.008 to 0.010 | 0.77 |
| Patients with prior PCI (%) | 0.013 | −0.008 to 0.034 | 0.17 |
| Short-term MACEs | |||
| No. of patients | −0.002 | −0.022 to 0.019 | 0.81 |
| Mean age (years) | −0.016 | −0.041 to 0.009 | 0.26 |
| Male (%) | 0.065 | −0.030 to 0.160 | 0.15 |
| DM (%) | −0.009 | −0.022 to 0.004 | 0.12 |
| Patients with prior PCI (%) | 0.015 | −0.027 to 0.056 | 0.46 |
| Long-term mortality | |||
| No. of patients | −0.011 | −0.050 to 0.028 | 0.66 |
| Mean age (years) | −0.016 | −0.105 to 0.073 | 0.52 |
| Male (%) | −0.018 | −0.044 to 0.008 | 0.12 |
| DM (%) | 0.006 | −0.009 to 0.021 | 0.26 |
| Patients with prior PCI (%) | 0.007 | −0.019 to 0.033 | 0.59 |
| Duration (years) | −0.022 | −0.096 to 0.051 | 0.39 |
CI, confidence interval; DM, diabetes mellitus; MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
Figure 4.Sensitivity analyses including only multivariate studies without acute PCI failure: (a) early all-cause mortality; (b) early MACEs; and (c) late all-cause mortality.
CI, confidence interval; MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
Figure 5.Funnel plots for the meta-analysis of the associations between prior PCI and outcomes after CABG: (a) early all-cause mortality; (b) early MACEs; and (c) late all-cause mortality.
CABG, coronary artery bypass grafting; MACEs, major adverse cardiovascular events; PCI, percutaneous coronary intervention.